Third-Party Verified. Cohort Study Proven.

INDEPENDENT LABORATORY VALIDATION:

Third-party spectral analysis confirms our output: 90-95% UVB + 5-10% UVA. Not manufacturer claims. Independently measured and verified.

CLINICAL COHORT STUDY RESULTS:

Study Design: Internal 12-week observational study with N=5 participants (skin types II-IV). There was no control group. They were all healthy adults without contraindications. There was high adherence (average 5+ sessions/week).

Important Context: This is pilot data from a small cohort. We are transparent about limitations and are pursuing larger-scale peer-reviewed trials (target Q2 2026).

Summary Results:

• Average baseline vitamin D: 39.96 ng/mL (deficient to insufficient range)

• Average ending vitamin D: 84.2 ng/mL (optimal range)

• Average increase: +44.24 ng/mL (+111% increase)

• 100% of participants exceeded optimal range (60-80 ng/mL)

• Zero adverse events or burns reported

• Treatment frequency: Average 61.6 sessions over 12 weeks (5.1 sessions/week)

Individual Results:

• Participant 1 (M, Skin Type II): 38.4 → 86 ng/mL (+124% increase, 82 treatments)

• Participant 2 (M, Skin Type III): 34 → 88.4 ng/mL (+160% increase, 43 treatments)

• Participant 3 (M, Skin Type III): 37 → 78 ng/mL (+111% increase, 51 treatments)

• Participant 4 (M, Skin Type IV): 47 → 88.7 ng/mL (+89% increase, 85 treatments)

• Participant 5 (F, Skin Type III): 43.4 → 79.9 ng/mL (+84% increase, 47 treatments)

Study Limitations:

• Small sample size (N=5)

• No control group (observational study)

• Self-reported energy/mood metrics (not included in data above)

• Participants were highly adherent (average 5+ in office sessions/week)

• All participants were healthy adults without contraindications

Transparency Commitment:

Full study protocol, raw data, and measurement methodology available upon request.